Revenue Recognition Revenue Recognition (Tables)

6 Months Ended

Dec. 31, 2018

Disaggregation of Revenue [Line Items]

Disaggregation of Revenue

The following tables allocate revenue for the three and six months ended December 31, 2018 by type of activity and reporting segment (in millions):

Three months ended December 31, 2018	Softgel Technologies		Biologics & Specialty Drug Delivery		Oral Drug Delivery		Clinical Supply Services		Total
Manufacturing & commercial product supply	$	197.0	$	88.6	$	100.5	$	—	$	386.1
Development services	16.7		95.7		53.5		—		165.9
Clinical supply services	—		—		—		80.8		80.8
Total	$	213.7	$	184.3	$	154.0	$	80.8	$	632.8
			Inter-segment revenue elimination						(9.8)
					Combined net revenue				$	623.0

Six months ended December 31, 2018	Softgel Technologies		Biologics & Specialty Drug Delivery		Oral Drug Delivery		Clinical Supply Services		Total
Manufacturing & commercial product supply	$	381.4	$	162.4	$	182.2	$	—	$	726.0
Development services	31.5		176.5		101.9		—		309.9
Clinical supply services	—		—		—		158.5		158.5
Total	$	412.9	$	338.9	$	284.1	$	158.5	$	1,194.4
			Inter-segment revenue elimination						(19.6)
					Combined net revenue				$	1,174.8

The following table allocates revenue by the location where the goods were made or the service performed:

(Dollars in millions)	Three months ended December 31, 2018		Six months ended December 31, 2018
United States	$	315.1	$	579.5
Europe	214.8		411.2
International Other	119.7		227.3
Elimination of revenue attributable to multiple locations	(26.6)		(43.2)
Total	$	623.0	$	1,174.8